Massachusetts Society of Clinical Oncologists - FDA Approves cabozantinib (CABOMETYX) for patients with HCC

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approves cabozantinib (CABOMETYX) for patients with HCC

FDA Approves cabozantinib (CABOMETYX) for patients with HCC

15 Jan 2019 2:45 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved cabozantinib (Cabometyz; Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org